La vendita allo scoperto per Eli Lilly dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Eli Lilly. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Eli Lilly (NYSE:LLY) Azioni, Report sulle vendite allo scoperto

Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co

Biotech

Large Cap

News

Health Care

Movers

General

Novo Nordisk presenta Amicretina: una pillola che raddoppia la perdita di peso rispetto a Wegovy e potrebbe rivoluzionare il trattamento.

L&#39;Amicretina raddoppia la perdita di peso rispetto a Wegovy

Equities

Markets

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Novo Nordisk annuncia risultati positivi per il farmaco contro l&#39;obesità infantile; richiesta di approvazione a FDA ed EMA.

Novo Nordisk: il farmaco per l&#39;obesità infantile mostra buoni risultati

Farmaci GLP-1 come Ozempic e Wegovy mostrano potenziale nella riduzione del rischio di cancro, secondo studi recenti e ricerche.

I farmaci per la perdita di peso potrebbero ridurre i rischi di cancro

HARVEST ELI LILLY HG CL U UNT ETF

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live Group

LIBERTY LIVE SERIES B by Liberty Media Corporation

Liberty Media Corporation - Series C Liberty Live Common Stock

Tidal Trust II Defiance Daily Target 2X Long LLY ETF

FDA Oks Eli Lilly's Selpercatinib For Medullary Thyroid Cancer

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is one of several companies benefitting from demand for weight loss drugs. The company is also seeing competition in the market including knockoff drugs that it said <a href="https://www.benzinga.com/general/biotech/24/08/40376247/dont-promote-copycat-weight-loss-drugs-amid-improved-supply-eli-lilly-asks-doctors-fda-evaluates">could be unsafe</a>.
What Happened: A recent report says Eli Lilly is seeking medical records of people who took knockoff <a href="https://www.benzinga.com/topic/weight-loss">weight loss drugs.</a>
The request, reported by <a href="https://www.bloomberg.com/news/articles/2024-09-19/lilly-wants-records-from-people-who-took-weight-loss-knockoffs?sref=TBDibEcD">Bloomberg</a>, is being done for safety reasons according to the pharmaceutical company.
Eli Lilly is building a case against businesses that are selling knockoffs of the company's Zepbound and Monjaro. Compounding pharmacies have been capitalizing on Lilly seeing supply constraints and shortages while demand remains high.
Lilly has said that the quality of the compounding pharmacies products are inferior and questions the safety profile of the treatment.
A letter viewed by Bloomberg requested information from a patient who took a Lilly product from a compounded pharmacy.
"We would appreciate if you could complete the enclosed form and sign the Authorization for Release of Medical Information so that we can obtain more details from the treating physician around your experience," the letter says.
Along with items like the letter, Eli Lilly also took out an advertisement in national publications encouraging patients to make sure they are taking the "real product."
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/09/41033009/can-novo-nordisks-weight-loss-drug-ozempic-help-stem-the-devastating-addiction-crisis-new-resear"> Can Novo Nordisk&#8217;s Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes</a>
Why It's Important: Obtaining medical records could be a key in Eli Lilly's battle against compounding pharmacies. The short supply of Lilly and other companies' weight loss drugs helped the argument for a legal loophole that allows compounding of drugs when a supply constraint happens.
If Eli Lilly can prove that the drugs are not as safe and are causing side effects or harm to patients, it could help put a stop to compounding pharmacies. Without proof, Eli Lilly may fall victim to the legal loophole and the issue of soaring demand for its own products.
Eli Lilly <a href="https://www.benzinga.com/general/biotech/24/08/40251130/mounjaro-maker-eli-lillys-bumper-q2-earnings-exceeds-estimates-hikes-outlook-again-on-strong-diab">reported second-quarter </a>revenue of $11.3 billion, up 36% year-over-year. Mounjaro and Zepbound had revenue of $3.1 billion and $1.2 billion, respectively, seeing significant gains in the quarter.
The pharmaceutical company increased its full-year guidance as a result of the second-quarter results and increasing demand for several products.
LLY Price Action: Eli Lilly stock closed Wednesday at $924.56 versus a 52-week trading range of $516.57 to $972.53. Eli Lilly stock is up 56% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41002452/eli-lillys-early-alzheimers-treatment-donanemab-scores-japanese-approval-its-second-largest-marke">Eli Lilly&#8217;s Early Alzheimer&#8217;s Treatment Donanemab Scores Japanese Approval, Its Second Largest Market</a></li>
</ul>
Photo: Shutterstock

Trading Ideas

Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments

A study compared the association of semaglutide vs other antidiabetic medications and other GLP-1RAs, including liraglutide and dulaglutide, with opioid overdose risk in patients with comorbid type 2 diabetes (T2D) and opioid use disorder (OUD).
Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide is available as Wegovy and Ozempic for weight loss and diabetes, respectively, and liraglutide is sold as Saxenda and Victoza.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41025381/exclusive-novo-nordisk-faces-political-heat-over-weight-loss-drug-prices-ahead-of-e" rel="noreferrer noopener">EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet &#8216;The Real Issue Is With The Middlemen&#8217;</a>.
Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) dulaglutide is available as Trulicity.
Drug overdose <a target="_blank" href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2824054?guestAccessKey=67ec89b0-a682-4fbf-97d9-1c0054b62d04&amp;utm_source=for_the_media&amp;utm_medium=referral&amp;utm_campaign=ftm_links&amp;utm_content=tfl&amp;utm_term=092524" rel="noreferrer noopener">deaths</a> in the U.S. remain alarmingly high, with an estimated 107,543 fatalities in 2023, primarily due to opioids.
Despite the proven effectiveness of medications for opioid use disorder (OUD) in reducing overdose risk, only about 25% of individuals with OUD receive treatment, and nearly half discontinue it within six months. This highlights the urgent need for alternative OUD therapies.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), commonly used to treat type 2 diabetes and obesity, have been shown to modulate dopamine reward pathways and reduce drug rewards, including heroin, in animal studies.
Additionally, anecdotal reports and studies have suggested that semaglutide may reduce drug cravings and offer therapeutic benefits in alcohol and nicotine use disorders.
These findings prompted an investigation into whether semaglutide could potentially help prevent overdoses in OUD patients.
Semaglutide was associated with a significantly lower risk of opioid overdose during a 1-year follow-up compared with other antidiabetic medications, including other GLP-1RAs, with HRs ranging from 0.32 to 0.58. 
The negative control outcome showed no difference between groups. The update signals a potential new use for the blockbuster diabetes medications.
The researchers noted that results need validation from other data resources and study populations. Further research is warranted to investigate the underlying mechanisms, and randomized clinical trials are necessary to corroborate the clinical effects on OUD.
The study utilized six years of data (between December 2017 and June 2023) from over 33,006 patients.
Earlier this year, a comprehensive U.S. study revealed that the use of&nbsp;Ozempic and Wegovy is not associated with an increased&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36509636/novo-nordisks-ozempic-and-wegovy-helps-lose-weight-not-ones-mind-us-study-find-no-increased-suici" rel="noreferrer noopener">risk of suicidal thoughts</a>.
Price Action: NVO stock is up 1.16% at $126.90, and LLY stock is down 0.05% at $924.01 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41031132/amgens-rocatinlimab-has-commercial-potential-despite-competitive-landscape-says-gol" target="_blank" rel="noreferrer noopener">Amgen&#8217;s Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs</a>.</li>
</ul>
Image via Shutterstock

Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users

A new study has found that people with a history of opioid abuse who took Novo Nordisk&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) <a href="https://www.benzinga.com/topic/ozempic">Ozempic</a> weight loss drug were significantly less likely to overdose, adding to growing evidence suggesting that the drug, primarily used for diabetes and weight loss, could help manage <a href="https://www.benzinga.com/topic/addiction">drug addiction</a>.
According to the <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.35247?guestAccessKey=67ec89b0-a682-4fbf-97d9-1c0054b62d04&amp;utm_source=for_the_media&amp;utm_medium=referral&amp;utm_campaign=ftm_links&amp;utm_content=tfl&amp;utm_term=092524" target="_blank" rel="noreferrer noopener">study</a>&nbsp;published Wednesday in JAMA Network Open, patients on semaglutide, the active ingredient in Ozempic and the weight-loss drug <a href="https://www.benzinga.com/topic/wegovy">Wegovy</a>, were less than half as likely to overdose compared to those on insulin. People taking semaglutide were 63% less likely to overdose than individuals on DPP-4 inhibitors, another common class of diabetes medication.
Rong Xu, professor of biomedical informatics at Cleveland's Case Western Reserve University, led the research, which had previously linked semaglutide to reductions in alcohol use disorder and smoking. This is the first large-scale study to evaluate opioid overdoses. 
The reduced risk associated with semaglutide persisted across most diabetes treatments, except for Eli Lilly and Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Trulicity, according to the study, which was first <a href="https://www.bloomberg.com/news/articles/2024-09-25/novo-s-ozempic-reduced-opioid-overdose-risk-research-shows?srnd=phx-latest&amp;sref=TBDibEcD&amp;leadSource=uverify%20wall">reported</a> by Bloomberg.
Read Also<a href="https://www.benzinga.com/general/biotech/24/09/40986953/novo-nordisk-ceo-to-face-senate-scrutiny-over-high-ozempic-and-wegovy-prices-hearing-scheduled-on">: Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday</a>
Why It Matters: Drug overdose deaths are at historically high levels in the U.S. 
Over 108,000 people died from an overdose in 2022, <a href="https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm" target="_blank" rel="noreferrer noopener">according to provisional data</a> released by the Centers for Disease Control and Prevention (CDC). In the one-year period ending in January 2024, there were over 76,922 fatal drug overdoses.
These overdose deaths are only part of the severity of the problem. 
&#8220;That overdose number is only looking at overdoses. It&#8217;s not looking at the person who dies of bacterial endocarditis related to their drug and alcohol use,&#8221; <a href="https://www.axios.com/2024/05/31/us-addiction-crisis-drug-use-disorder-mental-illness">said</a> Cara Poland, an addiction medicine doctor at the Michigan State University College of Human Medicine, per Axios.
As powerful new drugs like Ozempic grow in popularity for weight loss, interest is increasing in their potential to curb cravings for substances beyond food. Novo Nordisk is also exploring the drug&#8217;s effects on alcohol consumption in an ongoing clinical trial.
Now Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41025381/exclusive-novo-nordisk-faces-political-heat-over-weight-loss-drug-prices-ahead-of-e">EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet &#8216;The Real Issue Is With The Middlemen&#8217;</a>

Cannabis

Can Novo Nordisk's Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes

Investors with a lot of money to spend have taken a bullish stance on Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LLY, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 30 uncommon options trades for Eli Lilly.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 40%, bearish.
Out of all of the special options we uncovered, 9 are puts, for a total amount of $381,441, and 21 are calls, for a total amount of $1,724,773.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $300.0 to $1000.0 for Eli Lilly during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Eli Lilly options trades today is 370.19 with a total volume of 1,675.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Eli Lilly's big money trades within a strike price range of $300.0 to $1000.0 over the last 30 days.
<h3>Eli Lilly Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727289089_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$547.0</td>
<td>$537.0</td>
<td>$540.0</td>
<td>$420.00</td>
<td>$810.0K</td>
<td style="text-align: right;">17</td>
<td style="text-align: right;">15</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$217.15</td>
<td>$211.35</td>
<td>$217.15</td>
<td>$910.00</td>
<td>$108.5K</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$207.65</td>
<td>$205.9</td>
<td>$205.9</td>
<td>$820.00</td>
<td>$102.9K</td>
<td style="text-align: right;">90</td>
<td style="text-align: right;">5</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$6.0</td>
<td>$5.65</td>
<td>$6.0</td>
<td>$930.00</td>
<td>$102.6K</td>
<td style="text-align: right;">789</td>
<td style="text-align: right;">516</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$54.5</td>
<td>$50.55</td>
<td>$54.5</td>
<td>$680.00</td>
<td>$70.8K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">13</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Following our analysis of the options activities associated with Eli Lilly, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Eli Lilly</h3>
<ul>
<li>Trading volume stands at 1,094,643, with LLY's price up by 0.12%, positioned at $925.56.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 35 days.</li>
</ul>
<h3>Expert Opinions on Eli Lilly</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $1007.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Eli Lilly with a target price of $1100. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $885. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $885. 
&#x2A; An analyst from Morgan Stanley has revised its rating downward to Overweight, adjusting the price target to $1106. 
&#x2A; An analyst from Citigroup has revised its rating downward to Buy, adjusting the price target to $1060. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Eli Lilly with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Eli Lilly Unusual Options Activity

In an investor update on Tuesday,&nbsp;Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) released data from Phase 3 trials of rocatinlimab and Uplizna (inebilizumab).
HORIZON Phase 3 trial evaluated rocatinlimab for atopic dermatitis (eczema) <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41022603/amgens-rocatinlimab-data-beats-placebo-in-atopic-dermatitis-trial-but-analyst-says-" rel="noreferrer noopener">in 726 patients</a>.
Amgen&nbsp;<a target="_blank" href="https://investors.amgen.com/static-files/a7119a35-06de-497e-ba75-146404c54d95" rel="noreferrer noopener">reported</a> that rocatinlimab outperformed a placebo regarding the severity and extent of the disease.
Amgen stock is trading lower as the data seemed to be below expectations.
Goldman Sachs notes that although the Phase 3 efficacy data for rocatinlimab is less compelling compared to Dupixent, the analyst still sees strong commercial potential for the drug (if approved).
This is due to its favorable safety and tolerability profile, convenient dosing schedule, and the substantial total addressable market for atopic dermatitis, even with the high level of competition in the space, including Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Ebglyss (lebrikizumab) and Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>)&nbsp;amlitelimab.
The analysts view the recent updates as encouraging but note that the stock still doesn&#8217;t fully reflect the potential value of either asset.
The firm models peak sales for rocatinlimab in atopic dermatitis to reach around $4 billion by 2035 (with a 60% probability of success).
While not included in the model, the analyst sees a significant opportunity for Uplizna in generalized myasthenia gravis, estimating potential sales of about $2 billion.
Goldman Sachs maintains the Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/AMGN/analyst-ratings" rel="noreferrer noopener">price target of $370</a>.
Looking ahead, attention shifts to Amgen&#8217;s Phase 2 obesity data expected by the end of the year, where positive outcomes could lead to a stock re-rating to account for revenue potential and ease concerns about the upcoming loss of exclusivity in the <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40229568/amgens-mixed-q2-results-highlight-obesity-drug-potential-analysts-focus-shifts-to-u" rel="noreferrer noopener">latter half of the decade</a>.
Earlier this year, Amgen had the data from animal and early-stage human trials of its experimental obesity drug AMG 133 (maridebart cafraglutide)&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37318123/amgens-upcoming-catalysts-in-2024-set-to-unlock-multi-billion-dollar-markets-says-g" rel="noreferrer noopener">published in Nature Metabolism</a>.
The Journal confirmed the GIPR antagonist and GLP-1R agonist activities in cell-based systems and reported the ability of AMG 133 to reduce body weight and improve metabolic markers in male obese&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/36934096/weight-loss-drugs-new-entrant-amgen-to-compete-with-novo-nordisk-eli-lilly-as-investigational-wei" rel="noreferrer noopener">mice and cynomolgus monkeys</a>.&nbsp;
Price Action: AMGN stock is down 4.67% at $315.47 at last check Wednesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/41029568/masimo-names-interim-ceo-as-activist-board-members-step-in-joe-kiani-exits-amid-legal-clash" target="_blank" rel="noreferrer noopener">Masimo Names Interim CEO As Activist Board Members Step In; Joe Kiani Exits Amid Legal Clash</a>.</li>
</ul>

Analyst Color

Price Target

Reiteration

Analyst Ratings

AMGN

Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) revealed new long-term results on Wednesday, showing promise for treatment in patients with <a href="https://www.benzinga.com/general/biotech/24/09/40884197/eli-lilly-scores-fda-approval-for-eczema-treatment-ebglyss">moderate-to-severe atopic dermatitis</a>. 
What Happened: The company&#8217;s data for the ADjoin long-term extension study of Ebglyss (EHB-glihs) will be presented at the European Academy of Dermatology and Venereology Congress (EADV).
The EADV is a leading professional society focused on the fields of dermatology and venereology.
Over 80% of adults and adolescents with moderate-to-severe atopic dermatitis responded to Ebglyss treatment at Week 16 in the ADvocate 1 and 2 monotherapy trials. They continued treatment for up to three years and experienced sustained skin clearance with monthly maintenance dosing.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41002452/eli-lillys-early-alzheimers-treatment-donanemab-scores-japanese-approval-its-second-largest-marke" rel="noreferrer noopener">Eli Lilly&#8217;s Early Alzheimer&#8217;s Treatment Donanemab Scores Japanese Approval, Its Second Largest Market</a>.
Why It Matters: The FDA approved Ebglyss earlier this month for adults and children 12 years of age and older.
<ul>
<li>84% of the patients taking Ebglyss once monthly and 83% taking Ebglyss every two weeks maintained clear or almost-clear skin (IGA 0,1) at three years.</li>
<li>87% of the patients taking Ebglyss once monthly and 79% taking Ebglyss every two weeks achieved or maintained at least 90% improvement in disease extent and severity (EASI-90) at three years.</li>
<li>83% of the patients taking Ebglyss once monthly and 91% taking Ebglyss every two weeks did not require high-potency topical corticosteroids or systemic treatments.</li>
</ul>
Those who participated in the study have moderate-to-severe atopic dermatitis (eczema).
The European Union approved Ebglyss in 2023. Japan approved it in January; additional markets are expected to follow suit.
Lilly has exclusive rights for the development and commercialization of Ebglyss in the U.S. and elsewhere outside&nbsp;Europe.
In Europe, Lilly&#8217;s partner, Almirall, has licensed the rights to develop and commercialize Ebglyss for dermatology indications, including eczema.
Price Action: Eli Lilly stock is up 0.17% at $926 during the premarket session at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41023437/mercks-experimental-favezelimabkeytruda-combo-fails-in-late-stage-colorectal-cancer-study" target="_blank" rel="noreferrer noopener">Merck&#8217;s Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study</a></li>
</ul>
Image: Shutterstock

Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years

Over 80% Of Adults And Adolescents With Moderate-to-severe Atopic Dermatitis Who Responded To Eli Lilly's Ebglyss Treatment At Week 16 In ADvocate 1 And 2 Monotherapy Trials And Continued Treatment For Up To Three Years Experienced Sustained Skin Clearance With Monthly Maintenance Dosing

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has outperformed the market over the past 20 years by 6.08% on an annualized basis producing an average annual return of 14.48%. Currently, Eli Lilly has a market capitalization of $827.14 billion. 
Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 20 years ago, it would be worth $15,297.50 today based on a price of $918.62 for LLY at the time of writing.
<h3>Eli Lilly's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727202610_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Eli Lilly 20 Years Ago Would Be Worth This Much Today

Shares of Ventyx Biosciences (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtyx#NASDAQ">VTYX</a>) gained 7% on Monday after the company announced that it has entered into a $27 million strategic investment agreement with Sanofi. Per the terms of the deal, Sanofi will buy 70,601 of Ventyx&#39;s Series A non-voting convertible preferred stock for $3.8243 per share. Per the press release, each acquired preferred stock will initially be converted into 100 shares of common stock.&nbsp;
The proceeds from this investment are anticipated to enhance Ventyx&#39;s cash reserves. With the addition of these funds, the combined total of current cash, cash equivalents and marketable securities is expected to support the company&#39;s planned operations until at least the second half of 2026.
<h2>VTYX Grants SNY Exclusive Rights to Investigational Drug</h2>
In return for the $27 million equity investment, Ventyx has granted Sanofi the exclusive opportunity to first negotiate certain rights related to the clinical programs of VTYX&#39;s investigational candidate, VTX3232. Notably, VTX3232 is an oral, selective, central nervous system-penetrant NLRP3 inhibitor, which is being developed for various neuroinflammatory and neurodegenerative indications, including Parkinson&#39;s disease, cardiometabolic disease, Alzheimer&#39;s disease and multiple sclerosis.
Ventyx believes that this strategic deal with Sanofi underscores the potential of VTX3232 to offer a disease-modifying treatment for CNS indications with significant unmet medical needs. The company will also be able to utilize Sanofi&#39;s large resources and prowess in developing treatments for immunological and inflammatory diseases.
Year to date, shares of Ventyx have lost 0.4% compared with the industry&lsquo;s 1.5% decline.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/36/78953.jpg?v=1922698421" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
<h2>VTYX&#39;s Development Programs for VTX3232</h2>
Currently, Ventyx is developing VTX3232 for the treatment of Parkinson&#39;s disease and obesity. In early September, the company initiated a phase IIa study to evaluate VTX3232 in patients with early Parkinson&#39;s disease. Top-line results are expected in 2025.
Ventyx is also currently gearing up to initiate a separate 12-week phase II study of VTX3232 by the end of 2024 in patients with obesity and additional cardiovascular and cardiometabolic risk factors. The planned study will assess the impact of VTX3232 on key inflammatory biomarkers and weight change, both as a monotherapy and in combination with a GLP-1 receptor agonist. Top-line data from this obesity study of VTX3232 is also expected in 2025.
<div class="chart_embed">
<h2>Ventyx Biosciences, Inc. Price and Consensus</h2>
<img alt="Ventyx Biosciences, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/9b/1727179627.png" style="height:310px; width:600px" title="" />
Ventyx Biosciences, Inc. price-consensus-chart | Ventyx Biosciences, Inc. Quote
The obesity sector has garnered much interest in 2024 due to its huge untapped market potential. Several biotech firms are competing fiercely to enter this market and are evaluating candidates for the obesity indication.
</div>
The obesity market is currently dominated by two large drugmakers, Eli Lilly (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>) and Novo Nordisk (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvo#NYSE">NVO</a>),&nbsp;with their respective obesity drugs Zepbound (tirzepatide) and Wegovy (semaglutide). Despite having approved drugs in this space, LLY and NVO have been unable to cope with existing demand. Both companies have been investing heavily to ramp up production to meet increasing demand.
However, both NVO&#39;s Wegovy and LLY&#39;s Zepbound are administered as weekly injections. Novo Nordisk, Lilly and some other drugmakers are making oral medicines with different mechanisms of action for obesity, which can improve patient convenience.
<h2>Other Programs in VTYX&#39;s Clinical-Stage Pipeline</h2>
Apart from VTX3232, there are three early to mid-stage candidates in Ventyx&#39;s pipeline, VTX2735 (peripheral NLRP3 inhibitor), VTX002 (S1P1R modulator) and VTX958 (TYK2 inhibitor). While VTX2735 is being evaluated to treat cardiovascular and other systemic inflammatory diseases, VTX002 and VTX958 are under development for ulcerative colitis and Crohn&#39;s disease, respectively.
<h2>VTYX&#39;s Zacks Rank</h2>
Ventyx currently carries a Zacks Rank #3 (Hold).
<a href="https://www.zacks.com/stock/news/2340664/vtyx-stock-rises-on-strategic-equity-investment-deal-with-sny?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2340664">To read this article on Zacks.com click here.</a>

Penny Stocks

Small Cap

Events

VTYX

VTYX Stock Rises on Strategic Equity Investment Deal With SNY

Johnson &amp; Johnson&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>), via its subsidiary called Red River Talc, for the third time, filed for voluntary bankruptcy to resolve thousands of lawsuits related to its talc products. Red River Talc has filed for Chapter 11 bankruptcy to equitably resolve all of JNJ&#39;s present and future talc-related claims in a bankruptcy court in the Southern District of Texas.
JNJ faces more than 62,000 lawsuits for its talc-based products, primarily its baby powders. The lawsuits allege that its talc products contain asbestos, which caused many women to develop ovarian cancer. JNJ insists that talc-based products are safe and do not cause cancer. JNJ has permanently discontinued the sale of its talc-based Johnson&#39;s Baby Powder.
So far this year, JNJ&#39;s shares have risen 4.7% compared with the&nbsp;industry&#39;s 23.5% increase.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/52/78741.jpg?v=633076405" />
Image Source: Zacks Investment Research
<h2>JNJ&#39;s Two Failed Bankruptcy Attempts</h2>
Johnson &amp; Johnson&#39;s subsidiary, LTL Management, which was established to manage claims in the cosmetic talc litigation, filed for voluntary bankruptcy twice in New Jersey. However, both the bankruptcy filings were rejected by courts stating that J&amp;J was not in enough financial stress to qualify for bankruptcy.
<h2>JNJ&#39;s New Plan and 3rd Bankruptcy Filing</h2>
In May 2024, LTL Management proposed a new plan committing to pay claimants a present value of approximately $6.5 billion to be paid over 25 years, which could resolve 99.75% of all pending talc lawsuits against the company.
J&amp;J said that Red River filed the bankruptcy case after it received support from around 83% of current claimants for the proposed bankruptcy plan. This&nbsp;exceeds the 75% approval threshold required by the U.S. Bankruptcy Code to secure confirmation of the proposed plan. Red River also increased its settlement commitment by $1.75 billion to approximately $8 billion.
<h2>Several Rulings Against JNJ in Talc Lawsuits</h2>
Several juries have ruled against Johnson &amp; Johnson in talc lawsuits over the years. In one such ruling, in 2018, JNJ was ordered by a Missouri court to pay $4.7 billion in damages to 22 women who made such allegations, affirming a St. Louis court jury&#39;s verdict given earlier. Though the verdict was reduced to $2.1 billion by an appeals court in June 2020, it still rejected J&amp;J&#39;s appeal to overturn the 2018 jury verdict. JJohnson &amp; Johnson paid the award, which, including interest, totaled approximately $2.5 billion. In April 2023, J&amp;J offered to pay $8.9 billion over a period of 25 years to completely resolve its cosmetic talc litigation.
JNJ believes that resolving the claims via the civil law system would take years and incur significant costs for the company. The talc lawsuits have also hurt the company&#39;s goodwill and reputation. It believes that resolving the litigation through this proposed reorganization plan would be more efficient and would compensate claimants on time. &nbsp;However, some attorneys of the claimants feel Johnson &amp; Johnson is manipulating the bankruptcy process so that it can delay jury trials and also underpay the claimants. However, the higher settlement offer and a high percentage of claimant support may improve JNJ&#39;s chances of success after the previous two failures.
<h2>JNJ&#39;s Zacks Rank and Stocks to Consider</h2>
J&amp;J currently has a Zacks Rank #3 (Hold).
<div class="chart_embed">
<h3>Johnson &amp; Johnson Stock Price and Consensus</h3>
<img alt="Johnson &amp; Johnson Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/93/1727080281.png" style="height:265px; width:591px" title="" />
Johnson &amp; Johnson price-consensus-chart | Johnson &amp; Johnson Quote
Some better-ranked drug/biotech companies are Eli Lilly (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>), Pfizer&nbsp;and Bayer (OTC: <a class="ticker" href="https://www.benzinga.com/stock/bayry#OTC">BAYRY</a>). While Lilly sports a Zacks Rank #1 (Strong Buy), Pfizer and Bayer have a Zacks Rank #2 (Buy) each.
The Zacks Consensus Estimate for Lilly&#39;s 2024 earnings has risen from $13.78 to $16.49 per share over the past 60 days. For 2025, earnings estimates have risen from $19.44 to $23.97 per share over the same timeframe. Year to date, Lilly&#39;s stock has risen 58.1%.
</div>
Lilly beat estimates in each of the last four quarters, delivering a four-quarter average earnings surprise of 69.07%.
The Zacks Consensus Estimate for Pfizer&#39;s 2024 earnings has risen from $2.38 to $2.62 per share in the past 60 days, while that for 2025 has risen from $2.74 per share to $2.85 per share. Pfizer&#39;s shares have risen 2.2% year to date.
Pfizer beat estimates in each of the last four quarters, delivering a four-quarter average earnings surprise of 69.82%.
Estimates for Bayer&#39;s 2024 earnings have risen from $1.35 to $1.38 per share over the past 60 days. For 2025, earnings estimates have risen from $1.42 to $1.44 per share over the same timeframe. Year to date, Bayer&#39;s stock has declined 13.4%.
<a href="https://www.zacks.com/stock/news/2340100/johnson-johnson-files-for-bankruptcy-over-talc-lawsuits-for-the-third-time?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2340100">To read this article on Zacks.com click here.</a>

Earnings

Earnings Beats

Management

BAYRY

Johnson & Johnson Files for Bankruptcy Over Talc Lawsuits for the Third Time

On Tuesday, The Ministry of Health, Labour and Welfare Japan approved Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Kisunla (donanemab) for adults with early symptomatic Alzheimer&#8217;s disease (AD), which includes people with mild cognitive impairment (MCI) as well as people with the mild dementia stage of AD, with <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n40997545/lillys-kisunla-donanemab-azbt-approved-in-japan-for-the-treatment-of-early-symptomatic-alzheimers-" rel="noreferrer noopener">confirmed amyloid pathology</a>.
Japan&nbsp;is the second major market in which Kisunla has been approved for use.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40957505/eli-lilly-fights-183m-medicaid-fraud-judgment-cites-reasonable-interpretation-of-medicaid-rules" rel="noreferrer noopener">Eli Lilly Fights $183M Medicaid Fraud Judgment, Cites Reasonable Interpretation Of Medicaid Rules</a>.
In&nbsp;Japan, by 2030, the number of patients with dementia is estimated to be more than 5 million, and Alzheimer&#8217;s is the most common cause of dementia, accounting for more than 67% of cases.
Amyloid is a protein produced naturally in the body that can clump together to create amyloid plaques. The excessive buildup of amyloid plaques in the brain may lead to memory and thinking issues associated with Alzheimer&#8217;s disease.
Kisunla can help the body remove the excessive buildup of amyloid plaques and slow the decline.
The approval is based on the efficacy and safety data from TRAILBLAZER-ALZ 2 Phase 3 clinical study.
Those individuals treated with Kisunla who were less advanced in their disease showed a significant 35% slowing of decline compared with placebo on the integrated Alzheimer&#8217;s Disease Rating Scale (iADRS), which measures memory, thinking, and daily functioning.
In the overall population, the response to treatment was also statistically significant using the iADRS at 22%. Among the two groups analyzed, participants treated with Kisunla had up to a 39% lower risk of progressing to the next clinical stage of disease than those taking a placebo.
Among the overall population of participants, Kisunla reduced amyloid plaques on average by 61% at six months, 80% at 12 months, and 84% at 18 months compared to the start of the study.
In the TRAILBLAZER-ALZ 2 study, 66% of patients achieved plaque clearance at one year.
Kisunla can cause amyloid-related imaging abnormalities, which is a potential side effect with amyloid plaque-targeting therapies.
Price Action: LLY stock is trading higher by 0.05% to $919.01 premarket at the last check on Tuesday.
Photo via Shutterstock

Emerging Markets

Eli Lilly's Early Alzheimer's Treatment Donanemab Scores Japanese Approval, Its Second Largest Market

The application to the PMDA was based on the efficacy and safety data from TRAILBLAZER-ALZ 2 Phase 3 clinical study.

Eli Lilly Says Japan Has Approved Kisunla (Donanemab-azbt, 350 Mg/20 mL Every Four Weeks Injection For IV Infusion) For Early Symptomatic Alzheimer's Disease

Financial giants have made a conspicuous bearish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) revealed 12 unusual trades.
Delving into the details, we found 41% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $77,554, and 10 were calls, valued at $1,136,535.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $430.0 to $960.0 for Eli Lilly during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Eli Lilly's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly's whale trades within a strike price range from $430.0 to $960.0 in the last 30 days. 
<h3>Eli Lilly Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727099159_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$476.95</td>
<td>$470.95</td>
<td>$474.8</td>
<td>$450.00</td>
<td>$474.8K</td>
<td>0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$55.5</td>
<td>$53.75</td>
<td>$55.5</td>
<td>$930.00</td>
<td>$210.9K</td>
<td>26</td>
<td style="text-align: right;">38</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/27/24</td>
<td>$13.15</td>
<td>$11.0</td>
<td>$11.0</td>
<td>$920.00</td>
<td>$111.1K</td>
<td>262</td>
<td style="text-align: right;">20</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$9.5</td>
<td>$7.85</td>
<td>$9.5</td>
<td>$960.00</td>
<td>$95.0K</td>
<td>683</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/27/24</td>
<td>$2.1</td>
<td>$1.75</td>
<td>$1.75</td>
<td>$950.00</td>
<td>$52.5K</td>
<td>1.2K</td>
<td style="text-align: right;">278</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Having examined the options trading patterns of Eli Lilly, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Eli Lilly</h3>
<ul>
<li>Currently trading with a volume of 156,502, the LLY's price is down by -0.22%, now at $919.48. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 37 days.</li>
</ul>
<h3>Professional Analyst Ratings for Eli Lilly</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $1007.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $885. 
&#x2A; An analyst from Morgan Stanley downgraded its action to Overweight with a price target of $1106. 
&#x2A; An analyst from JP Morgan persists with their Overweight rating on Eli Lilly, maintaining a target price of $1100. 
&#x2A; Reflecting concerns, an analyst from Citigroup lowers its rating to Buy with a new price target of $1060. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $885.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Eli Lilly, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Spotlight on Eli Lilly: Analyzing the Surge in Options Activity

On Friday, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers (PBMs)—CVS Health Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) Caremark, Cigna Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) Express Scripts, and UnitedHealth Group Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) Optum—for allegedly engaging in unfair and anti-competitive practices that have inflated the list <a target="_blank" href="https://www.benzinga.com/government/24/07/39695378/ftc-investigation-uncovers-anti-competitive-practices-by-handful-of-pharmacy-benefit-managers-includ" rel="noreferrer noopener">price of insulin medications</a>.
The <a target="_blank" href="https://www.ftc.gov/news-events/news/press-releases/2024/09/ftc-sues-prescription-drug-middlemen-artificially-inflating-insulin-drug-prices" rel="noreferrer noopener">complaint</a> accuses the PBMs of creating a system that benefits them financially by prioritizing drug rebates, forcing patients to pay higher costs for life-saving insulin. These PBMs, referred to as the Big Three, administer around 80% of prescriptions in the U.S.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38564498/federal-trade-commission-targets-junk-patent-listings-for-diabetes-weight-loss-asthma-drugs-from-" rel="noreferrer noopener">Federal Trade Commission Targets &#8216;Junk Patent Listings&#8217; For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca</a>.
The FTC claims that the PBMs abused their market power to inflate insulin prices by promoting a rebate system with drug manufacturers.
This system led to the exclusion of lower-priced insulin from formularies, further driving up the cost for vulnerable patients.
The result is higher out-of-pocket expenses for those needing essential diabetes medication.
For example, the list price of Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Humalog rose dramatically from $21 in 1999 to over $274 in 2017.
Despite the availability of lower-priced alternatives, PBMs favored higher-priced drugs due to the lucrative rebates they provided.
The FTC is also examining the role of drug manufacturers, including Eli Lilly, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), in driving up insulin prices, signaling potential further action against these companies.
The rebate-driven system excluded lower-priced insulins and allowed the Big Three PBMs to keep significant revenue in the form of rebates and fees, a strategy that hurt patients while benefiting the PBMs financially.
Vulnerable patients, such as those with high deductibles or coinsurance, bore the brunt of these inflated costs, paying more for their insulin than the overall net cost to insurers.
Price Action: At last check Friday, CVS stock was down 1.61% at $57.49, UNH stock was down 0.29% at $575.39, and CI stock was up 0.07% at $357.52.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40961594/mullen-automotive-gears-up-210m-ev-deal-in-dubai-delivers-first-units-to-volt-mobility" target="_blank" rel="noreferrer noopener">Mullen Automotive Gears Up $210M EV Deal In Dubai – Delivers First Units To Volt Mobility</a>.</li>
</ul>
Photo by towfiqu barbhuiya via unsplash

Legal

US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices

FTC Alleges Pharmacy Benefit Managers Systematically Excluded Cheaper Insulins In Exchange For Expensive, Highly Rebated Alternatives

FTC Sues Units Of CVS Health , Cigna , And UnitedHealth For Allegedly Artificially Inflating Insulin Prices; FTC Case Does Not Name Insulin Drugmakers Eli Lilly, Novo Nordisk, And Sanofi , But Agency Reserves Right To Sue Later

In today's fast-paced and competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze companies before making investment decisions. In this article, we will conduct a comprehensive industry comparison, evaluating Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) against its key competitors in the Pharmaceuticals industry. By examining key financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.
<h3>Eli Lilly Background</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eli Lilly and Co</td>
<td>112.69</td>
<td>60.75</td>
<td>21.25</td>
<td>22.5%</td>
<td>$4.12</td>
<td>$9.13</td>
<td>35.98%</td>
</tr>
<tr>
<td>Novo Nordisk AS</td>
<td>45.06</td>
<td>35.80</td>
<td>15.70</td>
<td>18.97%</td>
<td>$35.74</td>
<td>$57.79</td>
<td>25.34%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
<td>24.93</td>
<td>5.55</td>
<td>4.68</td>
<td>6.62%</td>
<td>$7.8</td>
<td>$15.58</td>
<td>4.31%</td>
</tr>
<tr>
<td>Merck &amp; Co Inc</td>
<td>21.71</td>
<td>6.82</td>
<td>4.78</td>
<td>13.0%</td>
<td>$7.45</td>
<td>$12.37</td>
<td>7.16%</td>
</tr>
<tr>
<td>AstraZeneca PLC</td>
<td>38.30</td>
<td>6.19</td>
<td>5.02</td>
<td>5.01%</td>
<td>$4.12</td>
<td>$10.76</td>
<td>13.33%</td>
</tr>
<tr>
<td>Novartis AG</td>
<td>23.72</td>
<td>5.63</td>
<td>4.90</td>
<td>7.97%</td>
<td>$5.25</td>
<td>$9.7</td>
<td>9.6%</td>
</tr>
<tr>
<td>Sanofi SA</td>
<td>31.18</td>
<td>1.81</td>
<td>2.78</td>
<td>1.53%</td>
<td>$2.03</td>
<td>$7.97</td>
<td>6.53%</td>
</tr>
<tr>
<td>Zoetis Inc</td>
<td>37.89</td>
<td>17.63</td>
<td>9.95</td>
<td>12.45%</td>
<td>$0.97</td>
<td>$1.69</td>
<td>8.3%</td>
</tr>
<tr>
<td>GSK PLC</td>
<td>14.01</td>
<td>4.49</td>
<td>1.82</td>
<td>8.32%</td>
<td>$2.31</td>
<td>$5.76</td>
<td>9.84%</td>
</tr>
<tr>
<td>Takeda Pharmaceutical Co Ltd</td>
<td>45.13</td>
<td>0.86</td>
<td>1.52</td>
<td>1.26%</td>
<td>$388.51</td>
<td>$821.04</td>
<td>14.11%</td>
</tr>
<tr>
<td>Dr Reddy's Laboratories Ltd</td>
<td>19.69</td>
<td>3.71</td>
<td>3.79</td>
<td>4.84%</td>
<td>$21.72</td>
<td>$46.34</td>
<td>13.87%</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals PLC</td>
<td>18.85</td>
<td>1.83</td>
<td>1.99</td>
<td>4.52%</td>
<td>$0.36</td>
<td>$0.91</td>
<td>6.95%</td>
</tr>
<tr>
<td>Organon &amp; Co</td>
<td>5.20</td>
<td>36.08</td>
<td>0.82</td>
<td>203.12%</td>
<td>$0.43</td>
<td>$0.94</td>
<td>-0.06%</td>
</tr>
<tr>
<td>Corcept Therapeutics Inc</td>
<td>36.21</td>
<td>7.17</td>
<td>7.96</td>
<td>6.14%</td>
<td>$0.04</td>
<td>$0.16</td>
<td>39.15%</td>
</tr>
<tr>
<td>Prestige Consumer Healthcare Inc</td>
<td>18.07</td>
<td>2.18</td>
<td>3.33</td>
<td>2.94%</td>
<td>$0.08</td>
<td>$0.15</td>
<td>-4.36%</td>
</tr>
<tr>
<td>Average</td>
<td>27.14</td>
<td>9.7</td>
<td>4.93</td>
<td>21.19%</td>
<td>$34.06</td>
<td>$70.8</td>
<td>11.0%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>Through a thorough examination of Eli Lilly, we can discern the following trends: 
<ul>
<li>
The Price to Earnings ratio of 112.69 for this company is 4.15x above the industry average, indicating a premium valuation associated with the stock.
</li>
<li>
With a Price to Book ratio of 60.75, which is 6.26x the industry average, Eli Lilly might be considered overvalued in terms of its book value, as it is trading at a higher multiple compared to its industry peers.
</li>
<li>
The stock's relatively high Price to Sales ratio of 21.25, surpassing the industry average by 4.31x, may indicate an aspect of overvaluation in terms of sales performance.
</li>
<li>
With a Return on Equity (ROE) of 22.5% that is 1.31% above the industry average, it appears that the company exhibits efficient use of equity to generate profits.
</li>
<li>
The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $4.12 Billion is 0.12x below the industry average, suggesting potential lower profitability or financial challenges.
</li>
<li>
The gross profit of $9.13 Billion is 0.13x below that of its industry, suggesting potential lower revenue after accounting for production costs.
</li>
<li>
The company's revenue growth of 35.98% is notably higher compared to the industry average of 11.0%, showcasing exceptional sales performance and strong demand for its products or services.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726844413_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio gauges the extent to which a company has financed its operations through debt relative to equity.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
When comparing Eli Lilly with its top 4 peers based on the Debt-to-Equity ratio, the following insights can be observed:
<ul>
<li>
Compared to its top 4 peers, Eli Lilly has a moderate debt-to-equity ratio of 2.13, indicating a balanced financial structure.
</li>
<li>
This suggests that the company maintains a reasonable level of debt while also leveraging equity financing.
</li>
</ul>
<h3>Key Takeaways</h3>
For Eli Lilly, the PE, PB, and PS ratios are all high compared to its peers in the Pharmaceuticals industry, indicating potentially overvalued stock. On the other hand, Eli Lilly's high ROE and revenue growth suggest strong performance relative to industry standards. However, the low EBITDA and gross profit levels may raise concerns about the company's operational efficiency and profitability compared to its competitors in the sector.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Analysis: Eli Lilly Versus Competitors In Pharmaceuticals Industry

On Wednesday, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has urged a federal appeals court to overturn a $183 million judgment stemming from accusations of defrauding Medicaid.
The case, initiated in 2014, alleges that Eli Lilly underreported drug prices to Medicaid, resulting in smaller rebates owed to the program.
Last week,&nbsp;Walgreens Boots Alliance&nbsp;Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) agreed to pay $106.8 million to settle allegations that it submitted false claims to government healthcare programs, violating the False Claims Act&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40881893/walgreens-agrees-to-106-8m-settlement-over-alleged-false-billing-claims" rel="noreferrer noopener">and state regulations</a>.
The U.S. pharma giant claims it is being wrongfully held liable despite adhering to its interpretation of Medicaid&#8217;s complex rebate requirements.
The claims also highlight that Eli Lilly failed to disclose price increases billed to distributors, which were not reflected in its Medicaid pricing reports.
Reuters noted that Eli Lilly started reporting price increases after a 2017 rule change, though the company claims it had previously informed regulators about its pricing practices without facing any objections.
In 2022, a U.S. District Judge rejected Eli Lilly&#8217;s motion for summary judgment, ruling that its price statements were misleading and allowing the case to proceed. In May 2023, a jury found Eli Lilly responsible for $61 million in damages, which were tripled to $183 million under the federal False Claims Act.
Most recently, Oak Street Health, a subsidiary of&nbsp;CVS Health&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), agreed to settle for $60 million following allegations that it violated the <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40945496/cvs-subsidiary-oak-street-health-agrees-to-60m-settlement-in-medicare-kickback-violations" rel="noreferrer noopener">False Claims Act</a>.
The&nbsp;<a target="_blank" href="https://www.justice.gov/opa/pr/oak-street-health-agrees-pay-60m-resolve-alleged-false-claims-act-liability-paying-kickbacks" rel="noreferrer noopener">claims</a> involved paying kickbacks to third-party insurance agents to recruit seniors to its primary care clinics, a practice that led to false Medicare submissions.
The case has garnered attention from major business groups, including the U.S. Chamber of Commerce and Pharmaceutical Research and Manufacturers of America (PhRMA). These organizations argue that upholding the judgment would create uncertainty for regulated companies.
Price Action: LLY stock is trading higher by 1.45% to $928.28 premarket at the last check on Friday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40955083/holiday-opportunity-macys-plans-to-hire-31-500-seasonal-workers" target="_blank" rel="noreferrer noopener">Holiday Opportunity: Macy&#8217;s Plans To Hire 31,500 Seasonal Workers</a>.</li>
</ul>
Photo via Shutterstock

Eli Lilly Fights $183M Medicaid Fraud Judgment, Cites Reasonable Interpretation Of Medicaid Rules

Novartis (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvs#NYSE">NVS</a>) announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population.
The regulatory body approved Kisqali in combination with an aromatase inhibitor for the adjuvant treatment of people with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast cancer (EBC) at high risk of recurrence, including those with node-negative (N0) disease.
Kisqali is a selective cyclin-dependent kinase inhibitor, a class of drugs that helps slow the progression of cancer by inhibiting two proteins &mdash; cyclin-dependent kinase 4 and 6 (CDK4/6).
The broad indication in HR+/HER2- stage II and III EBC at high risk of recurrence approximately doubles the population eligible for CDK4/6 inhibitor adjuvant therapy.
Year to date, shares of Novartis have risen 14.6% compared with the industry&#39;s growth of 24.1%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/e0/78240.jpg?v=1246149801" /> 
Image Source: Zacks Investment Research
<h2>Broader Label for NVS&#39; Kisqali</h2>
The FDA approval is based on strong results from the late-stage NATALEE trial. The results showed a significant and clinically meaningful 25.1% reduction in risk of disease recurrence in a broad population of patients with HR+/HER2- stage II and III EBC treated with adjuvant Kisqali plus endocrine therapy&nbsp;compared to ET alone, including those with high-risk N0 disease.
The invasive disease-free survival benefit was consistently observed across all patient subgroups.
Please note that Kisqali is already approved for the treatment of metastatic breast cancer (MBC) in several countries.
The latest FDA approval of Kisqali for this early breast cancer population, including those with N0 disease, should enable NVS to offer treatment with a CDK4/6 inhibitor to a significantly broader group of patients.
NVS recently presented an updated analysis from the NATALEE trial at the European Society for Medical Oncology Congress 2024. Results showed that Kisqali caused a deepening benefit beyond the three-year treatment period and reduced the risk of recurrence by 28.5% compared to ET alone, in patients with stage II and III HR+/HER2- EBC.
Novartis will continue to evaluate NATALEE patients for long-term outcomes, including overall survival.
<h2>Kisqali: A Top Drug for NVS</h2>
Kisqali is one of the key growth drivers for NVS, which is now a pure-play innovative medicine company with a focus on core therapeutic areas &mdash; cardiovascular, renal and metabolic, immunology, neuroscience and oncology.
It is one of the leading breast cancer drugs in the United States and outside the country, with a dominant market share. The drug generated sales worth $1.3 billion in the first half of 2024.
Approximately 90% of breast cancer cases in the United States are diagnosed early (stages I-III). These patients remain at risk of cancer recurrence (in most cases as an incurable metastatic disease).
The drug&#39;s approval for a broader population should further fuel sales.
Regulatory reviews for Kisqali as an EBC treatment are ongoing worldwide, including in the EU and China.
Last year, the FDA also expanded Eli Lilly&#39;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>) Verzenio&#39;s (abemaciclib) indication. Verzenio, a CDK4/6 inhibitor, was approved in combination with ET for the adjuvant treatment of HR+HER2-, node-positive, EBC at a high risk of recurrence.
Eli Lilly is witnessing a stupendous run in 2024, riding high on the success of its GLP-1 drugs &mdash; Mounjaro and Zepbound.
<h2>NVS&#39; Zacks Rank &amp; A Stock to Consider</h2>
NVS currently carries a Zacks Rank #3 (Hold).
A better-ranked stock from the large-cap pharma industry is Pfizer, which currently sports a Zacks Rank #2 (Buy).
Estimates for PFE&#39;s 2024 earnings have risen from $2.39 to $2.62 per share over the past 60 days. For 2025, the bottom-line estimate has risen from $2.75 to $2.85 over the same time frame.
<a href="https://www.zacks.com/stock/news/2337925/novartis-wins-fda-approval-of-kisqali-for-early-breast-cancer?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2337925">To read this article on Zacks.com click here.</a>

Novartis Wins FDA Approval of Kisqali for Early Breast Cancer

Eli Lilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) short percent of float has risen 14.71% since its last report. The company recently reported that it has 6.27 million shares sold short, which is 0.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.41 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Eli Lilly Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726605911_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Eli Lilly has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Eli Lilly's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Eli Lilly's peer group average for short interest as a percentage of float is 4.49%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Eli Lilly's Recent Short Interest

Novo Nordisk, Lilly weight loss drugs poised for price reductions: Cantor's Louise Chen

Novo Nordisk's Ozempic could have another benefit: reducing opioid overdoses

BioAge, obesity drug developer, upsizes proposed IPO

Amgen stock slides 5% as analysts weigh in on drug study results (update)

Next frontier in anti-obesity landscape: oral GLP-1s with potential OTC switch

SPY: Still Hanging In Balance

BioAge stock rallies 29% following upsized $198M IPO

As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term growth. Investors looking to capitalize on this trend might consider adding healthcare giants like Eli Lilly and Company (LLY), UnitedHealth Group (UNH), and Merck & Co. (MRK) to their watchlist. Read more… The growing number of elderly people worldwide is fueling a surge in demand for healthcare services, pharmaceuticals, and insurance, giving the healthcare sector a significant tailwind. Additionally, with technological advancements and innovative treatments on the rise, the future of the industry looks brighter than ever.
Amid this backdrop, investors looking to invest in the healthcare sector could keep an eye on fundamentally strong companies like Eli Lilly and Company (<a href="https://stocknews.com/stock/LLY/">LLY</a>), UnitedHealth Group Incorporated (<a href="https://stocknews.com/stock/UNH/">UNH</a>), and Merck &amp; Co., Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>), which are well-positioned to capitalize on this demographic shift.
According to a report, one in five Americans will be 65 or older by 2040, reaching a <a href="https://www.urban.org/policy-centers/cross-center-initiatives/program-retirement-policy/projects/data-warehouse/what-future-holds/us-population-aging">total of 80 million</a>. As the global population ages, the need for biopharma products and modern, effective drugs to manage long-term diseases is poised to increase more than ever. The pharmaceuticals market is forecasted to generate $1.45 trillion in revenue by 2029, <a href="https://www.statista.com/outlook/hmo/pharmaceuticals/worldwide">exhibiting a CAGR of 4.7%</a>.
Additionally, the health insurance sector, particularly those offering Medicare-related products and services, is poised to capitalize on this trend. As per Precedence Research, the global health insurance market is anticipated to hit $5.12 trillion by 2034, growing at a <a href="https://precedenceresearch.com/health-insurance-market">CAGR of 7.4%</a>.
Considering these conducive trends, let's look at the fundamentals of the above-mentioned stocks in detail:
Eli Lilly and Company (<a href="https://stocknews.com/stock/LLY/">LLY</a>)
LLY is a medicine company that discovers, develops, manufactures, and markets human pharmaceuticals worldwide. The company offers medicines for diabetes, obesity, rheumatoid arthritis, plaque psoriasis, ulcerative colitis, depressive disorder, and others, in addition to oncology products.
On September 24, LLY announced that the Ministry of Health, Labour and Welfare of Japan approved Kisunla for treating adults with early symptomatic Alzheimer's disease (AD), which includes people with mild cognitive impairment (MCI) and those with mild dementia stage of AD. This treatment will help reduce the infusion burden for eligible patients.  
On September 13, LLY received approval from the U.S. Food and Drug Administration (FDA) for EBGLYSS (lebrikizumab-lbkz), a targeted IL-13 inhibitor. This biologic treatment is intended for adults and children aged 12 years and above with moderate-to-severe atopic dermatitis that is not well controlled with topical therapies. It aims to provide long-lasting efficacy to patients with a maintenance dose administered once a month for a year.
For the second quarter (ended June 30, 2024), LLY reported revenue of $11.30 billion, representing a 36% growth from the prior-year quarter. It reported a non-GAAP gross profit of $9.27 billion, indicating a 39.8% growth from the prior year quarter with a margin of 80.8% (up 250 bps year-over-year).
In addition, its operating income increased 74.8% year-over-year to $3.71 billion. The company's non-GAAP <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> came in at $3.54 billion and $3.92 per share, up 85.9% and 85.8% year-over-year, respectively.
The company has updated its fiscal year 2024 guidance, increasing its revenue projection by $3 billion to a range of $45.40 billion to $46.60 billion. LLY's EPS is anticipated to fall between $15.10 and $15.60. On a consolidated adjusted basis, its non-GAAP EPS is expected to range from $16.10 to $16.60.
Street expects LLY's revenue for the fiscal third quarter (ending September 2024) to increase 26.5% year-over-year to $12.01 billion. Its EPS for the current quarter is expected to improve substantially from the year-ago value to $4.50. Moreover, it beat the EPS estimates in each of the trailing four quarters, which is promising.
Shares of LLY have surged 65.3% over the past year and 59.3% over the past nine months to close the last trading session at $909.32.
LLY's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this robust outlook. The stock has an overall rating of B, which equates to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
LLY has an A grade for Sentiment and a B for Growth. It is ranked #37 out of 157 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry. <a href="https://stocknews.com/stock/LLY/">Click here</a> to see the additional ratings for LLY (Value, Momentum, Stability, and Quality).
UnitedHealth Group Incorporated (<a href="https://stocknews.com/stock/UNH/">UNH</a>)
UNH operates as a diversified health care company. The company operates through four segments: UnitedHealthcare; Optum Health; Optum Insight; and Optum Rx.
On September 17, the UNH Community Plan of New Mexico announced a collaboration with the school-based healthcare provider Goodside Health to provide and expand integrated physical and behavioral healthcare services to 50 New Mexico schools, with an investment of $250,000. This collaboration will help school children gain healthier access to primary care as well as mental health care.
On August 29, UNH announced a three-year strategic partnership with Goodwill Industries International, involving a $4.5 million investment, to increase access to education and training, support health-related social needs, and create workforce development opportunities. This partnership aims to help people overcome barriers that prevent them from obtaining employment and to create opportunities for job seekers.
In the fiscal second quarter that ended on June 30, 2024, UNH's total revenue increased 6.4% year-over-year to $98.86 billion. The company's adjusted net earnings came in at $6.31 billion, up 9.3% year-over-year, while its adjusted EPS grew 10.7% from the year-ago value to $6.80.
According to the financial guidance for fiscal year 2024, the company's adjusted earnings per share is anticipated to range from $27.50 to $28.
The consensus revenue estimate of $99.28 billion for the fiscal third quarter (ending September 2024) represents a 7.5% increase year-over-year. The consensus EPS estimate of $7.06 for the same quarter indicates a 7.6% improvement year-over-year. The company has an impressive surprise history; it surpassed the consensus revenue and EPS estimates in each of the trailing four quarters.
The stock has surged 18.8% over the past three months to close the last trading session at $574.81.
UNH's mixed fundamentals are reflected in its POWR Ratings. The stock has a B grade for Stability and Sentiment. It is ranked #5 out of 10 stocks in the A-rated <a href="https://stocknews.com/category/health-insurance/">Medical - Health Insurance</a> industry.
Beyond what is stated above, we've also rated UNH for Growth, Value, Momentum, and Quality. Get all UNH's ratings <a href="https://stocknews.com/stock/UNH/">here</a>.
Merck &amp; Co., Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>)
MRK is a global health care company offering health solutions through its prescription medicines, including biological therapies, vaccines, and animal health products. It operates through two segments: Pharmaceutical and Animal Health.
On September 25, MRK received new approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for KEYTRUDA's significant role as a combination therapy and as a monotherapy for certain patients with urothelial carcinoma.
On September 18, MRK announced that the U.S. Food and Drug Administration (FDA) approved KEYTRUDA in combination with pemetrexed and platinum chemotherapy as a first-line treatment option for adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
MRK's sales for the second quarter ended June 30, 2024, increased 7.2% year-over-year to $16.11 billion, while its KEYTRUDA product sales improved by 15.9% from the year-ago value to $7.27 billion. The company's non-GAAP net income stood at $5.81 billion compared to the prior-year quarter's loss of $5.22 billion, while its non-GAAP EPS came in at $2.28 versus a loss of $2.06 per share last year.
According to the full-year 2024 guidance, MRK forecasts worldwide sales to range from $63.40 billion to $64.40 billion, an increase from the previous guidance of $63.10 billion to $64.30 billion. The company also expects non-GAAP EPS to be between $7.94 and $8.04.
Analysts expect MRK's revenue for the fourth quarter (ending December 2024) to increase 7.1% year-over-year to $15.67 billion, while its EPS for the same period is expected to grow significantly from the prior year to $1.91. Moreover, the company topped the consensus revenue estimates in each of the trailing four quarters.
Over the past year, the stock has gained 7.3%, closing the last trading session at $113.09.
MRK's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It also has an A grade for Quality and a B for Value and Stability. Within the Medical - Pharmaceuticals industry, it is ranked #7 out of 157 stocks. <a href="https://stocknews.com/stock/MRK/">Click here</a> to see MRK's ratings for Growth, Momentum, and Sentiment.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
LLY shares were trading at $884.11 per share on Friday morning, down $25.21 (-2.77%). Year-to-date, LLY has gained 52.41%, versus a 21.84% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/lly-unh-mrk-3-healthcare-stocks-to-watch-as-the-aging-population-drives/>3 Healthcare Stocks to Watch as the Aging Population Drives Demand</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare Stocks to Watch as the Aging Population Drives Demand

Bristol Cobenfy approval draws optimism from Street, though with caveats

Lilly gets traditional FDA approval for Retevmo for thyroid cancer

ABBV

AMZN

ARGX

AVGO

BIOA

NVDA

OTSKF

OTSKY

REGN

RHHBF

RHHBY

VKTX

ZLAB

Screenshot 2024-09-10 at 4.29.40 PM

BRTX

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

TNXP

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-24 at 12.03.42 AM

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Screenshot 2024-02-22 at 11.51.01 PM

BTTX

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Press Releases

In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin

Lilly appoints Lucas Montarce as executive vice president and chief financial officer

Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes

With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes

Commodities

Lilly expands manufacturing footprint in Ireland with $1.8 billion investment

FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis

Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease

As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse

New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis

AMRX

NTRB

NTRBW

TEVA

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Eli Lilly

Vendite allo scoperto

Eli Lilly (NYSE:LLY) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO